The Hereditary Cancer Clinic (HCC) at the Georgia Cancer Center offers a 1-year, advanced fellowship in hereditary cancer knowledge, clinical practice, program development, and research.
The HCC has a rapidly growing program in genetics and cancer risk management, with over 1,000 new patient referrals expected in 2024 and a 25% positive test rate. HCC practitioners obtain a personal and family cancer history and conduct genetic testing on probands and family members, followed by comprehensive cancer genetic risk assessment for those whose tests reveal the presence of a monogenic disorder as well as management of surveillance and subspecialty referrals.
Consultation service for Variant of Uncertain Significance (VUS) resolution
Remote testing for family members
Management of genetic cancer risk in positive patients and family members
Coordination of subspecialty referrals
Extension of genetic services into oncology practice
Soon-to-be launched telegenetics service
Several subspecialty clinics are located within the HCC, including:
Cancer Pharmacogenomics Program.The program is directed by Katherine Saunders, RPh and John W Henson, MD, and conducts genetic testing forDYPDandUGT1A1alleles to inform dose and side effect considerations for capecitabine, 5-FU, and irinotecan.
Georgia Neurofibromatosis Clinic.This clinic specializes in the management of patients of all ages with neurofibromatosis types 1 and 2. Clinics are conducted at Children’s Hospital of Georgia and the Georgia Cancer Center.
Pediatric Cancer Predisposition Clinic.This clinic is held at the Children's Hospital of Georgia and specializes in assessing genetic cancer risk in children and young people up to age 18 years.
TSC ClinicTM.The TSC Clinic is designated by the TSC Alliance as one of two sites in Georgia that specialize in the management of individuals with tuberous sclerosis complex. Twelve medical and surgical specialties participate in this clinic.
VHL Alliance Clinical Care CenterTM.Georgia Cancer Center is the only VHL Alliance designated site in our state that provides specialized genetic, diagnostic, and therapeutic expertise, including access to the new HIF2-alpha inhibitor belzutifan.
Contact Us
Interested individuals should send a CV & letter of interest to
